Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome – the AEGIS-II Study

Principal Investigator: Earl Hope, MD

Sub-investigators: Eric Elgin, MD

Study Objectives: To evaluate the efficacy of CSL112 on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects with ACS (diagnosed with STEMI or NSTEMI)

Inclusion Criteria:
- Male or female at least 18 years of age
- Evidence of myocardial necrosis in a clinical setting consistent with type 1 MI
- Evidence of multivessel coronary artery disease
- Established protocol defined risk factors
- Post-menopausal, negative pregnancy test and acceptable protocol defined methods of contraception

Exclusion Criteria:
- Hemodynamic instability defined by protocol
- Evidence of hepatobiliary disease
- Evidence of severe chronic kidney disease
- Plan to undergo scheduled coronary artery bypass graft surgery after randomization
- Allergic to investigational product or soy beans or peanuts
- Severe comorbid conditions defined by the protocol

Affiliations & Sponsors: CSL Behring

Status: Open to Enrollment

Keywords: ACS, NSTEMI, STEMI, Apolipoprotein A-I